1. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Issue 15 (20th May 2022) Authors: Harrison, Claire N.; Garcia, Jacqueline S.; Somervaille, Tim C.P.; Foran, James M.; Verstovsek, Srdan; Jamieson, Catriona; Mesa, Ruben; Ritchie, Ellen K.; Tantravahi, Srinivas K.; Vachhani, Pankit; O'Connell, Casey L.; Komrokji, Rami S.; Harb, Jason; Hutti, Jessica E.; Holes, Leanne; Masud, Abdul... Journal: Journal of clinical oncology Issue: Volume 40:Issue 15(2022) Page Start: 1671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addressing symptom burden in myeloproliferative neoplasms. Issue 2 (June 2022) Authors: Tremblay, Douglas; Mesa, Ruben Journal: Baillière's best practice and research in clinical haematology Issue: Volume 35:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. (August 2022) Authors: Rippel, Noa; Tremblay, Douglas; Zubizarreta, Nicole; Podoltsev, Nikolai; Gotlib, Jason; Heaney, Mark; Kuykendall, Andrew; O'Connell, Casey; Shammo, Jamile M.; Fleischman, Angela; Kremyanskaya, Marina; Hoffman, Ronald; Mesa, Ruben; Yacoub, Abdulraheem; Mascarenhas, John Journal: Leukemia research Issue: Volume 119(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Association of the blood eosinophil count with hematological malignancies and mortality. Issue 3 (16th January 2015) Authors: Andersen, Christen L.; Siersma, Volkert D.; Hasselbalch, Hans C.; Vestergaard, Hanne; Mesa, Ruben; Felding, Peter; Olivarius, Niels D.F.; Bjerrum, Ole W. Journal: American journal of hematology Issue: Volume 90:Issue 3(2015:Mar.) Page Start: 225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Associations Between Global Mental Health and Response to an App-Based Meditation Intervention in Myeloproliferative Neoplasm Patients. (June 2020) Authors: Puzia, Megan E.; Huberty, Jennifer; Eckert, Ryan; Larkey, Linda; Mesa, Ruben Journal: Integrative cancer therapies Issue: Volume 19(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?. Issue 11 (November 2017) Authors: Mesa, Ruben; Harrison, Claire Journal: Lancet Issue: Volume 4:Issue 11(2017) Page Start: e508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. (3rd January 2016) Authors: Mesa, Ruben; Verstovsek, Srdan; Kiladjian, Jean‐Jacques; Griesshammer, Martin; Masszi, Tamas; Durrant, Simon; Passamonti, Francesco; Harrison, Claire N.; Pane, Fabrizio; Zachee, Pierre; Zhen, Huiling; Jones, Mark M.; Parasuraman, Shreekant; Li, Jingjin; Côté, Isabelle; Habr, Dany; Vannucchi, Ales... Journal: European journal of haematology Issue: Volume 97:Number 2(2016:Aug.) Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Issue 7 (2nd July 2016) Authors: Mughal, Tariq I.; Abdel-Wahab, Omar; Rampal, Raajit; Mesa, Ruben; Koschmieder, Steffen; Levine, Ross; Hehlmann, Rüdiger; Saglio, Giuseppe; Barbui, Tiziano; Van Etten, Richard A. Journal: Leukemia & lymphoma Issue: Volume 57:Issue 7(2016:Jul.) Page Start: 1517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38–44]. (June 2019) Authors: Gerds, Aaron T.; Tauchi, Tetsuzo; Ritchie, Ellen; Deininger, Michael; Jamieson, Catriona; Mesa, Ruben; Heaney, Mark; Komatsu, Norio; Minami, Hironobu; Su, Yun; Shaik, Naveed; Zhang, Xiaoxi; DiRienzo, Christine; Zeremski, Mirjana; Chan, Geoffrey; Talpaz, Moshe Journal: Leukemia research Issue: Volume 81(2019) Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. Issue 11 (17th August 2017) Authors: Begna, Kebede; Al‐Kali, Aref; Elliott, Michelle; Foran, James; Gangat, Naseema; Hogan, William; Hook, Christopher; Leis, Jose; Litzow, Mark; Mesa, Ruben; Palmer, Jeanne; Pardanani, Animesh; Patnaik, Mrinal; Rivera, Candido; Sproat, Lisa; Tibes, Raoul; Wolanskyj‐Spinner, Alexandra; Tefferi, Ayalew Journal: American journal of hematology Issue: Volume 92:Issue 11(2017:Nov.) Page Start: E626 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗